Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FATE - Fate Therapeutics Inc


IEX Last Trade
3.68
0.140   3.804%

Share volume: 1,046,976
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.54
0.14
3.96%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
10%
Profitability 0%
Dept financing 7%
Liquidity 75%
Performance 4%
Company vs Stock growth
vs
Performance
5 Days
-4.43%
1 Month
-28.46%
3 Months
6.38%
6 Months
-48.60%
1 Year
39.02%
2 Year
-85.87%
Key data
Stock price
$3.68
P/E Ratio 
-2.38
DAY RANGE
N/A - N/A
EPS 
-$1.69
52 WEEK RANGE
$1.63 - $8.83
52 WEEK CHANGE
$0.31
MARKET CAP 
417.932 M
YIELD 
N/A
SHARES OUTSTANDING 
113.878 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
2.75
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,164,457
AVERAGE 30 VOLUME 
$1,643,371
Company detail
CEO: John Wolchko
Region: US
Website: http://fatetherapeutics.com/
Employees: 482
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

Recent news